GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » FCF Margin %

NKGen Biotech (NKGen Biotech) FCF Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. NKGen Biotech's Free Cash Flow for the three months ended in Mar. 2024 was $-4.03 Mil. NKGen Biotech's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, NKGen Biotech's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, NKGen Biotech's current FCF Yield % is -31.10%.

The historical rank and industry rank for NKGen Biotech's FCF Margin % or its related term are showing as below:


During the past 3 years, the highest FCF Margin % of NKGen Biotech was -4696.48%. The lowest was -29506.49%. And the median was -17101.49%.

NKGN's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -143.92
* Ranked among companies with meaningful FCF Margin % only.

NKGen Biotech FCF Margin % Historical Data

The historical data trend for NKGen Biotech's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech FCF Margin % Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23
FCF Margin %
-4,696.48 -29,506.49 -

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
FCF Margin % Get a 7-Day Free Trial - - - - -

Competitive Comparison of NKGen Biotech's FCF Margin %

For the Biotechnology subindustry, NKGen Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NKGen Biotech's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NKGen Biotech's FCF Margin % distribution charts can be found below:

* The bar in red indicates where NKGen Biotech's FCF Margin % falls into.


NKGen Biotech FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

NKGen Biotech's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-21.996/0
= %

NKGen Biotech's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-4.034/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NKGen Biotech FCF Margin % Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

NKGen Biotech (NKGen Biotech) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » FCF Margin %
Comparable Companies
OCUP CASI SPRO XLO NGM GBIO ASMB CCCC OCEA FIXX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
19700 Fairchild Road, Suite No. 300, Irvine, CA, USA, 92612
Website
https://www.nkgenbiotech.com
NKGen Biotech Inc is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform.